Our Anti-Kir3.3 mouse monoclonal primary antibody from NeuroMab is produced in-house from hybridoma clone N455/15. It is KO validated, detects human, mouse, and rat Kir3.3, and is purified by Protein A chromatography. It is great for use in IHC, ICC.
Potassium inwardly rectifying channel subfamily J member 9 is encoded by the gene KCNJ9. KCNJ9 is a member of the inward rectifier-type potassium channel (TC 1.A.2.1) family, KCNJ9 subfamily. KCNJ9 is an integral membrane protein and inward-rectifier type potassium channel, which has a greater tendency to allow potassium to flow into the cell rather than out of the cell. KCNJ9 is controlled by G-proteins and associates with another G-protein-activated potassium channel to form a heteromultimeric pore-forming complex. KCNJ9 is expressed in the brain and skeletal muscle. Diseases associated with KCNJ9 include Pendred Syndrom and Seizures, Sensorineural Deafness, Ataxia, Mental Retardation, and Electrolyte Imbalance.
Purified by Protein A chromatography
Fusion protein amino acids 1-21 and 341-393 (fusion of cytoplasmic N- and C-termini) of mouse Kir3.3 (accession number P48543) produced recombinantly in E. Coli
Human, Mouse, Rat
Aliquot and store at ≤ -20°C for long term storage. For short term storage, store at 2-8°C. For maximum recovery of product, centrifuge the vial prior to removing the cap.
Produced by in vitro bioreactor culture of hybridoma line followed by Protein A affinity chromatography and conjugation of purified mAb. Purified mAbs are >90% specific antibody.
PBS with 0.09% azide
FL594 Ex: 594 nm, Em: 615 nm
No cross-reactivity reported
Each new lot of antibody is quality control tested by western blot on rat whole brain lysate and confirmed to stain the expected molecular weight band.
These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.